levels of multiple metabolites changed drastically during the assay. We show that these 23 changes compromise the robustness of the assay and make it difficult to reproduce. 24 25 We then devised 'metabolically rationalized standard' assay conditions, in which 26 glutaminase-1 inhibition reduced glutamine metabolism differently in both cell lines assayed, 27 and decreased the proliferation of one of them. The adoption of optimized conditions such 28
as the ones described here should lead to an improvement in reproducibility and help 29 eliminate false negatives as well as false positives in these assays. 30
1 Introduction 36 37 Reproducibility has increasingly become a topic of concern in biomedical research 1,2 . 38 Scientists acknowledge that they fail to reproduce even their own experiments, let alone 39 those of their colleagues around the globe 3 . When testing a potential anticancer drug, a 40 novel and potent allosteric inhibitor specific for the glutaminase-1 enzyme (EC 3.5.1.2), we 41 initially experienced a similar irreproducibility. Our focus on metabolomics led us to 42 experiments that then produced an explanation for the lack of reproducibility, and employed 43 a more comprehensive assay development approach which we believe can be of benefit for 44 the scientific community. 45 46 One of the initial steps in the development of therapeutic agents for cancer involves testing 47 these agents in vitro using human cancer cell lines as experimental models 4,5 . Using primary 48 cell lines in culture, the effects of compounds or perturbations on cell proliferation, DNA 49 replication or cell death is generally investigated over a period of time. These types of read-50 out are highly dependent on cell physiology and as such these assays need to fulfill a 51 number of conflicting conditions. On the one hand, cells need to be kept in culture long 52 enough to attain a steady state and for the effects of treatments to be observed. On the 53 other hand, they should not be kept there too long because of the gradual accumulation of 54 waste products that can be inhibitory or toxic to cells, such as lactate and ammonia 6 . The 55 concentration of nutrients will fall over time, pH will change, and as cells grow and divide, 56 space may become limiting. As cell density increases, effects of paracrine signaling become 57 more pronounced and as cells reach confluence, contact inhibition may suppress 58 proliferation. Although cancer cells are able to proliferate for some time after reaching 59 confluence by then accumulating on top of one another, this crowding still limits individual 60 cells' access to nutrients and growth factors 7 , eventually resulting in cell cycle arrest and 61 apoptosis, but long before then, in shifts in cell metabolism. Cell viability assays are affected 62 by the metabolic state of the cells and therefore any shift in metabolic states during the 63 assay, and particularly different shifts between sensitive and resistant cell lines, would 64 confound the outcome of such assays. 65
66
Recently, Haibe-Kains et al. highlighted multiple inconsistencies between two large-scale 67 pharmacogenomic studies, the Cancer Genome Project (CGP 8 ) and the Cancer Cell Line 68 Encyclopedia (CCLE 9 ), viz. the sensitivity profiles of common cell lines and drugs 10 . It has 69 been suggested that differences in the cell culture conditions were amongst the reasons for 70 4 these discrepancies 11 and that consistency should be achievable with appropriate laboratory 71 and analysis protocols 12 . For example, for each cell line the CGP study determined the 72 seeding density that ensured that each was still in the growth phase at the end of the assay 73 (~70% confluence), whilst the seeding density was not reported for the CCLE study 8 . In 74 addition, for adherent cells, the test compound was added 'around 12-24 hours' after 75 seeding cells and studied over a further 72-84 hours in the CCLE study, whereas in the 76 CGP study this was added 1 day after seeding and assayed 72 hours after treatment. This 77 lack of standardized and well-described culture conditions is common to most literature in 78 this field (see refs. [13] [14] [15] [16] [17] [18] [19] for examples). Living cells are complex; they adjust to altering 79 environments, by quick metabolic or somewhat slower gene-expression regulation and this 80 may readily change the extent to which any target limits cell physiology and survival. This 81 can make results of drug targeting studies irreproducible unless the relevant environmental 82 conditions are well controlled at the appropriate time scale. Both academia and the 83 pharmaceutical industry recognize the necessity of much more thorough standardization to 84 improve reproducibility 20 . 85
86
The metabolic performance of the cell lines during drug targeting assays is not assessed 87 routinely, or at least not reported. Metabolic changes could have strong implications for 88 therapeutic targets in, or affected by, intermediary metabolism. Metabolic enzymes involved 89 in cellular proliferation and growth have been identified as altered in cancers, either through 90 the expression of cancer-specific isoforms, through mutations, or through altered expression 91 levels 21 . And it is precisely these targets that are witnessing revived interest of late 22,23 : these 92 altered metabolic pathways are now being targeted directly, used to enhance the efficacy of 93 existing therapeutic agents or to overcome resistance to current treatment strategies for 94 cancer. In addition, anti-cancer drugs that do not target metabolism itself are often assayed 95 in survival based assays. If metabolism is so involved in cell survival, its variability and 96 during survival based assays could therefore be a prime cause of irreproducibility of the 97 outcome of the many experimental assays. We thus investigated whether variability in 98 cellular metabolic status is linked with different phenotypic responses. 99 of this inhibitor on cell survival was determined 48-hours later. We used two cell lines, A549 117 and H358, that are dependent on glutamine for proliferation 24 , but differ in sensitivity to a 118 novel and potent inhibitor of GLS1 activity developed jointly by AstraZeneca and Cancer 119
Research Technology: proliferation of A549 cells is inhibited by this 'GLS1i', whereas 120 proliferation of H358 cells is insensitive to GLS1 inhibition ( Figure S1 ). 121
The problem: the inhibitor does not seem to work 122 123
We had expected that treatment with a GLS1 inhibitor would lead to a reduced consumption 124 of glutamine, a reduced production of glutamate, an increased intracellular concentration of 125 glutamine, a reduced intracellular concentration of glutamate and reduced intracellular 126 concentrations of all TCA cycle intermediates, particularly in the GLS1i sensitive A549 cell 127 lines. The initially observed effects of GLS1i treatment were very different to what we 128 expected ( Table 1) The fluctuating environment that the cells were exposed to in this assay likely contributed to 165 the changes in the specific growth rate of these cells: a small increase in cell numbers was 166 observed over the first 24 hours post dosing ( Figure 2c Indeed, we observed steadier metabolic conditions and cell proliferation when the initial 203 seeding density of cells was reduced and the volume of culture media increased from 1 to 3 204 mL (Figure 3 and Figure S5 ). The period of time during which cells were able to grow 205 exponentially was also increased (Figure 3 ). Ensuring that confluence remained below ~ 80 206 % throughout the assay window (24-72 hours post seeding), or that this level of confluence 207 was reached as late as possible in the assay, required a significant reduction in the initial 208 8 seeding density of cells, and this was cell-line specific. The time required to recover from 209 reseeding also differed between cell lines and was affected by the initial seeding density. 210
This initial lag phase was very short in duration for A549 cells (< 6 hours) compared to the 211 approximately 24 hours required by H358 cells (Figure 3) , which extended beyond 24 hours 212 when H358 cells were seeded at 2 × 10 5 cells/well. These differences in growth kinetics 213 could well compromise inhibitor assays. 214
215
Lowering the initial seeding density of cells also reduced the magnitude of changes in the 216 concentrations of key nutrients such as glucose and glutamine ( Figure S5b and c) , and in pH 217 ( Figure S5a ) throughout the assay window (24-72 hours post seeding). In the case of the 218 H358 cell line, using these conditions, assays beyond 48 hours after seeding may not be 219 suitable since these cells displayed a high rate of glucose consumption ( Figure S5b ) and the 220 corresponding lactate secretion would lead to significant reductions in pH ( Figure S5a) . 221
When H358 cells were seeded at 3 x 10 5 cells/well, the concentration of glucose reached 222 limiting levels (~2 mM) 72 hours after seeding, which would constitute 48 hours post dosing 223 in an assay where treatment was applied 24 hours after seeding ( Figure S5b) . 224
225
We conclude that, in order to ensure that (1) To validate the expected improvement in assay performance we then seeded A549 and 236 H358 cells at a density of 1.5 × 10 5 and 3 × 10 5 cells/well respectively in 3 mL of media in a 237 6 well plate format. Cells were growing exponentially at rates comparable to those reported 238 in the literature 26 ( Figure S6 ) throughout the assay in control conditions. From plates 239 prepared in parallel, the levels of various metabolites in cell and spent media extracts as well 240 as cell numbers were measured for 24 hours after treatment with 1 μM of the GLS1 inhibitor. 241
In agreement with our expectations (Table 1) , treatment with the GLS1 inhibitor over 24 242 hours led to a reduction in cell numbers of around 20% in A549 cells but not in H358 cell 243 9 lines (Figure 4a ). Throughout the assay, the changes in the cells' environment were now 244 minimal in both cell lines regardless of treatment conditions (Figure 4b-f ): the concentrations 245 of glucose and glutamine were reduced by less than 50% over the assay and the lactate 246 secreted caused a pH drop < 1 unit under these improved assay conditions. The amount of 247 glutamine consumed appeared reduced in both cell lines by treatment with the GLS1 248 inhibitor although these changes were small and only statistically significant in A549 cells: 249 the achieved stability of culture conditions had the consequence that differences in cellular 250 metabolism were no longer strongly reflected in the changes of the exometabolome, such 251 that assay conditions were now under control and steady. 252
253
We therefore assessed intracellular metabolism to investigate whether, under the optimized 254 conditions, the predicted effects of GLS1i on intracellular metabolites were observed that 255 had not been observed under the previous unstable conditions ( Table 1) . Our results confirm 256 that the glutaminase inhibitor engaged with the intended target: large reductions (p < 0.01) in 257 glutamate were observed in both cell lines (Figure 5a ). Only minor increases in the 258 concentration of glutamine were seen, probably as a result of rapid equilibration with the 259 external medium via the glutamine transporter (Figure 5b) . The intracellular abundance of 260 TCA cycle intermediates was also affected by GLS1i treatment in both cell lines (Figure 5c The assay with which we started this study failed to demonstrate any consistent effects of 270 glutaminase inhibition on either glutamine metabolism or proliferation in these two cancer 271 cell lines: addition of the inhibitor to cells (A549) known to be sensitive to the inhibitor, had 272 no apparent effect on their proliferation ( Figure S2a) . Conversely, the glutamine metabolism 273 by cells (H358) that are insensitive to the same inhibitor was reduced to a much greater 274 extent than that by sensitive (A549) cells (Figure 1 ). We then demonstrated that these 275 inconsistencies were artifacts, for one, because most glutamine had been depleted in the 276 pre-incubation period (Figure 1b and 2b) leaving too little glutamine for effects of the inhibitor 277 to become statistically noteworthy. 278 10 279 With our improved assay conditions we were able to show that the glutaminase inhibitor 280 (GLS1i) does have an effect on glutamine metabolism of both cell lines, but that only the 281 proliferation of the A549 cells is reduced (Figure 4) . GLS1 inhibition was also apparent from 282 the changes in levels of intracellular metabolites in both cell lines, but with distinct 283 differences between sensitive (A549) and resistant (H358) cell lines ( Figure 5) . 284
285
Our findings highlight the importance of in vitro assay optimization for the assessment of the 286 potential of metabolic, and probably also other, inhibitors as anti-cancer drugs that impact on 287 cellular metabolism. Variability in the metabolic state during the assay may well create false 288 positives and false negatives because intermediary and energy metabolism is full of 289 pleiotropic implications. Importantly perhaps, the implications of our findings are unlikely to 290 be limited to studies of metabolic inhibitors. Other inhibitors, such as those of cell signaling 291 or transcription require even longer cell incubations, and may therefore be compromised 292 even more by changes in the levels of metabolites such as ATP, NADH, acetyl-CoA and 293 glutamate that cross-talk widely. Even though metabolism may not be the drug target in 294 these cases, its perturbation due to inappropriate culture conditions, might produce a false 295 response. And since the drug may well affect metabolism indirectly, the impact of metabolic 296 status could be overlooked in both control and treated conditions. 297
298
Perhaps even more so than this, our results should warn against the straightforward 299 implementation of historically-fixed sets of conditions for drug assays in cell lines. Living 300 cells are complex enough to engage in all sorts of metabolic changes, these changes may 301 well differ between individual cell lines, and the metabolome is sensitive to such changes 302 well before the metabolic fluxes produced by the cells are 33 . We therefore advocate that 303 data, points that are of critical concern 37 . 326 327 A number of reporting guidelines for the results of biological assays have been in existence 328 for some time, e.g. the Minimum Information About a Microarray Experiment (MIAME) 329 standard. MIAME is now a reporting requirement for a number of funding agencies and 330 journals 38 . Similarly, there are now minimum reporting standards in use for metabolomics 35 
